AbbVie has received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) for atogepant, an oral calcitonin gene-related peptide receptor antagonist, as a prophylaxis of migraine in adults who have four or more migraine days per month. If approved by the European Commission, AbbVie will be the only company to offer a once-daily treatment spanning both chronic and episodic migraines in the EU. The decision was based on two Phase 3 studies that evaluated atogepant's efficacy in reducing mean monthly migraine days compared to placebo.
Keywords: AbbVie, atogepant, CHMP, migraine, prophylaxis
Migraine is a debilitating neurological disease that affects over one billion people worldwide. It imposes both a social and financial burden on individuals and healthcare systems. Atogepant offers a new therapeutic option for those living with this condition.
AbbVie has been granted a positive opinion by the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) regarding its drug at